Evidence map›Paper›PMID 25520249›Full record

Trial reportInternational journal of obesity (2005)2015

Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial.

R V Seimon, D Espinoza, N Finer, W P T James, U F Legler, W Coutinho, A M Sharma, L Van Gaal, A P Maggioni, A Sweeting and 3 more

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in International journal of obesity (2005), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Anti-obesity drug discovery: advances and challenges.Nature reviews. Drug discovery · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 6 countries.

R V SeimonThe Boden Institute of Obesity, Nutrition Exercise & Eating Disorders, University of Sydney, Sydney, New South Wales, Australia.
D EspinozaNational Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.
N FinerNational Centre for Cardiovascular Prevention and Outcomes, University College London, Institute for Cardiovascular Science, London, UK.ORCID 0000000324686804
W P T JamesLondon School of Hygiene and Tropical Medicine, London, UK.
U F LeglerSpecial Vocational College for Handicapped Persons, Mainz, Germany.
W CoutinhoCatholic University of Rio de Janeiro and State Institute of Diabetes and Endocrinology, Rio de Janeiro, Brazil.
A M SharmaDepartment of Medicine, University of Alberta, Edmonton, Alberta, Canada.
L Van GaalDepartment of Diabetology, Metabolism and Clinical Nutrition, Antwerp University Hospital, Antwerp, Belgium.
A P MaggioniAssociazione Nazionale Medici Cardiologi Ospedalieri Research Center, Florence, Italy.
A SweetingThe Boden Institute of Obesity, Nutrition Exercise & Eating Disorders, University of Sydney, Sydney, New South Wales, Australia.
C Torp-PedersenDepartment of Cardiology, Gentofte University Hospital, Hellerup, Denmark.ORCID 0000000328926131
V GebskiNational Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.
I D CatersonThe Boden Institute of Obesity, Nutrition Exercise & Eating Disorders, University of Sydney, Sydney, New South Wales, Australia.
The University of Sydney · AUAntwerp University Hospital · BEAssociazione Nazionale Medici Cardiologi Ospedalieri · ITGentofte Hospital · DKLondon School of Hygiene & Tropical Medicine · GBUniversity College London · GBUniversity of Alberta · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesThe Sibutramine Cardiovascular OUTcomes (SCOUT) trial showed a significantly increased relative risk of nonfatal cardiovascular events, but not mortality, in overweight and obese subjects receiving long-term sibutramine treatment with diet and exercise. We examined the relationship between early changes (both increases and decreases) in pulse rate, and the impact of these changes on subsequent cardiovascular outcome events in both the placebo and sibutramine groups. SUBJECTS/

methods9804 males and females, aged ⩾55 years, with a body mass index of 27-45 kg m(-)(2) were included in this current subanalysis of the SCOUT trial. Subjects were required to have a history of cardiovascular disease and/or type 2 diabetes mellitus with at least one cardiovascular risk factor, to assess cardiovascular outcomes. The primary outcome event (POE) was a composite of nonfatal myocardial infarction, nonfatal stroke, resuscitated cardiac arrest or cardiovascular death. Time-to-event analyses of the POE were performed using Cox regression models.

resultsDuring the initial 6-week sibutramine treatment period, the induced pulse rate increase was related to weight change (1.9±7.7 beats per minute (bpm)  with weight increase; 1.4±7.3 bpm, 0-5 kg weight loss; 0.6±7.4 bpm, ⩾5 kg weight loss). Throughout the subsequent treatment period, those continuing on sibutramine showed a consistently higher mean pulse rate than the placebo group. There was no difference in POE rates with either an increase or decrease in pulse rate over the lead-in period, or during lead-in baseline to 12 months post randomization. There was also no relationship between pulse rate at lead-in baseline and subsequent cardiovascular events in subjects with or without a cardiac arrhythmia.

conclusionBaseline pulse rate and changes in pulse rate may not be an important modifier nor a clinically useful predictor of outcome in an individual elderly cardiovascular obese subject exposed to weight management.

Indexed as

AgedAppetite DepressantsBody Mass IndexCardiovascular DiseasesCyclobutanesDiabetic AngiopathiesFemaleHeart RateHumansMaleMiddle AgedObesityPredictive Value of TestsRisk FactorsTreatment OutcomeUnited KingdomAppetite DepressantsCyclobutanessibutramine

Identifiers

PMID25520249
OpenAlexW2048236522

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.